Compare $SKYE vs $VSBC | Chartloom

Compare

$SKYE vs $VSBC

Skye Bioscience Inc · Vitaspring Biomedical Co. Ltd

SKYE

Skye Bioscience Inc

VSBC

Vitaspring Biomedical Co. Ltd

Compare $SKYE vs $VSBC

Comparing Skye Bioscience Inc and Vitaspring Biomedical Co. Ltd

SKYESkye Bioscience Inc

VSBCVitaspring Biomedical Co. Ltd

SKYESkye Bioscience Inc

Market cap

$59M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-75.9%

52W performance

-87.7%

FCF yield

-65.4%

VSBCVitaspring Biomedical Co. Ltd

Market cap

$7M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-100.0%

52W performance

-100.0%

FCF yield

0.1%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

SKYE

VSBC

Detailed metrics comparison

SKYE

Skye Bioscience Inc

VSBC

Vitaspring Biomedical Co. Ltd

Market Cap

SKYE$59M

VSBC$7M

Enterprise Value

SKYE$51M

VSBC$9M

Price

SKYE$1.69

VSBC$0.00

P/E Ratio

SKYEN/A

VSBCN/A

P/S Ratio

SKYE26.57x

VSBC0.99x

EV/Sales

SKYE0.00x

VSBC0.99x

EV/EBITDA

SKYE0.00x

VSBC4.29x

P/B Ratio

SKYE0.83x

VSBC3.92x

P/FCF Ratio

SKYEN/A

VSBC765.53x

EV/FCF

SKYE-1.31x

VSBC1,044.32x

PEG Ratio

SKYEN/A

VSBCN/A

Forward P/E (NTM)

SKYEN/A

VSBCN/A

Forward P/S (NTM)

SKYEN/A

VSBCN/A

Revenue (TTM)

SKYE$0

VSBC$0

Revenue Growth (YoY)

SKYEN/A

VSBCN/A

Forward Rev Growth

SKYE307.4%

VSBC0.0%

Gross Margin (TTM)

SKYE39.3%

VSBC39.3%

Operating Margin (TTM)

SKYE0.0%

VSBC23.4%

EBITDA Margin (TTM)

SKYE0.0%

VSBC0.0%

Net Margin (TTM)

SKYE0.0%

VSBC18.2%

FCF Margin (TTM)

SKYEN/A

VSBCN/A

Net Income (TTM)

SKYE$-50M

VSBC$-456K

FCF (TTM)

SKYE$-39M

VSBC$9K

EPS (TTM)

SKYE-$10.18

VSBC-$0.00

ROE (TTM)

SKYE-21727.0%

VSBC70.0%

ROA (TTM)

SKYE-20179.0%

VSBC-211240.0%

ROIC (TTM)

SKYE-21675.0%

VSBC70.0%

Cash

SKYE$9M

VSBC$13K

Debt

SKYE$143K

VSBC$2M

Net Cash/Debt

SKYE$8M

VSBC$-2M

Current Ratio (TTM)

SKYE0.95x

VSBC0.00x

Quick Ratio (TTM)

SKYE0.91x

VSBC0.00x

Debt/Equity (TTM)

SKYE0.03x

VSBC0.00x

Debt/Assets (TTM)

SKYE0.0%

VSBC0.0%

Interest Coverage (TTM)

SKYEN/A

VSBCN/A

Net Debt/EBITDA (TTM)

SKYE0.00x

VSBC0.00x

Beta

SKYE3.13

VSBC-1.47

52W Performance

SKYE-87.7%

VSBC-100.0%

YTD Performance

SKYE-75.9%

VSBC-100.0%

% from 52W High

SKYE-88.0%

VSBC-100.0%

% from 52W Low

SKYE12.7%

VSBCN/A

Asset Turnover (TTM)

SKYE1.93x

VSBC2.66x

FCF Yield (TTM)

SKYE-65.4%

VSBC0.1%

Earnings Yield (TTM)

SKYE-85.0%

VSBC-6.9%

Dividend Yield (TTM)

SKYEN/A

VSBCN/A

Rule of 40

SKYE0.0

VSBC0.0

EV/GP/RG

SKYEN/A

VSBCN/A

Ticker research

View SKYE research View VSBC research

Metric	SKYE Skye Bioscience Inc	VSBC Vitaspring Biomedical Co. Ltd
Market & Valuation
Market Cap	$59M	$7M
Enterprise Value	$51M	$9M
Price	$1.69	$0.00
P/E Ratio	N/A	N/A
P/S Ratio	26.57x	0.99x
EV/Sales	0.00x	0.99x
EV/EBITDA	0.00x	4.29x
P/B Ratio	0.83x	3.92x
P/FCF Ratio	N/A	765.53x
EV/FCF	-1.31x	1,044.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	307.4%	0.0%
Profitability
Gross Margin (TTM)	39.3%	39.3%
Operating Margin (TTM)	0.0%	23.4%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	18.2%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-50M	$-456K
FCF (TTM)	$-39M	$9K
EPS (TTM)	-$10.18	-$0.00
ROE (TTM)	-21727.0%	70.0%
ROA (TTM)	-20179.0%	-211240.0%
ROIC (TTM)	-21675.0%	70.0%
Financial Health
Cash	$9M	$13K
Debt	$143K	$2M
Net Cash/Debt	$8M	$-2M
Current Ratio (TTM)	0.95x	0.00x
Quick Ratio (TTM)	0.91x	0.00x
Debt/Equity (TTM)	0.03x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.13	-1.47
52W Performance	-87.7%	-100.0%
YTD Performance	-75.9%	-100.0%
% from 52W High	-88.0%	-100.0%
% from 52W Low	12.7%	N/A
Efficiency & Yields
Asset Turnover (TTM)	1.93x	2.66x
FCF Yield (TTM)	-65.4%	0.1%
Earnings Yield (TTM)	-85.0%	-6.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View SKYE research	View VSBC research

Valuation

P/S Ratio

VSBC

0.99x

SKYE

26.57x

EV/FCF

SKYE

-1.31x

VSBC

1,044.32x

Growth & revenue

Forward Revenue Growth

SKYE

307.4%

VSBC

0.0%

Profitability & performance

Gross Margin

VSBC

39.3%

SKYE

39.3%

ROE

VSBC

70.0%

SKYE

-21727.0%

FCF Yield %

VSBC

0.1%

SKYE

-65.4%

52-Week Performance

SKYE

-87.7%

VSBC

-100.0%

Detailed metrics comparison

SKYE

Skye Bioscience Inc

VSBC

Vitaspring Biomedical Co. Ltd

Market Cap

SKYE$59M

VSBC$7M

Enterprise Value

SKYE$51M

VSBC$9M

Price

SKYE$1.69

VSBC$0.00

P/E Ratio

SKYEN/A

VSBCN/A

P/S Ratio

SKYE26.57x

VSBC0.99x

EV/Sales

SKYE0.00x

VSBC0.99x

EV/EBITDA

SKYE0.00x

VSBC4.29x

P/B Ratio

SKYE0.83x

VSBC3.92x

P/FCF Ratio

SKYEN/A

VSBC765.53x

EV/FCF

SKYE-1.31x

VSBC1,044.32x

PEG Ratio

SKYEN/A

VSBCN/A

Forward P/E (NTM)

SKYEN/A

VSBCN/A

Forward P/S (NTM)

SKYEN/A

VSBCN/A

Revenue (TTM)

SKYE$0

VSBC$0

Revenue Growth (YoY)

SKYEN/A

VSBCN/A

Forward Rev Growth

SKYE307.4%

VSBC0.0%

Gross Margin (TTM)

SKYE39.3%

VSBC39.3%

Operating Margin (TTM)

SKYE0.0%

VSBC23.4%

EBITDA Margin (TTM)

SKYE0.0%

VSBC0.0%

Net Margin (TTM)

SKYE0.0%

VSBC18.2%

FCF Margin (TTM)

SKYEN/A

VSBCN/A

Net Income (TTM)

SKYE$-50M

VSBC$-456K

FCF (TTM)

SKYE$-39M

VSBC$9K

EPS (TTM)

SKYE-$10.18

VSBC-$0.00

ROE (TTM)

SKYE-21727.0%

VSBC70.0%

ROA (TTM)

SKYE-20179.0%

VSBC-211240.0%

ROIC (TTM)

SKYE-21675.0%

VSBC70.0%

Cash

SKYE$9M

VSBC$13K

Debt

SKYE$143K

VSBC$2M

Net Cash/Debt

SKYE$8M

VSBC$-2M

Current Ratio (TTM)

SKYE0.95x

VSBC0.00x

Quick Ratio (TTM)

SKYE0.91x

VSBC0.00x

Debt/Equity (TTM)

SKYE0.03x

VSBC0.00x

Debt/Assets (TTM)

SKYE0.0%

VSBC0.0%

Interest Coverage (TTM)

SKYEN/A

VSBCN/A

Net Debt/EBITDA (TTM)

SKYE0.00x

VSBC0.00x

Beta

SKYE3.13

VSBC-1.47

52W Performance

SKYE-87.7%

VSBC-100.0%

YTD Performance

SKYE-75.9%

VSBC-100.0%

% from 52W High

SKYE-88.0%

VSBC-100.0%

% from 52W Low

SKYE12.7%

VSBCN/A

Asset Turnover (TTM)

SKYE1.93x

VSBC2.66x

FCF Yield (TTM)

SKYE-65.4%

VSBC0.1%

Earnings Yield (TTM)

SKYE-85.0%

VSBC-6.9%

Dividend Yield (TTM)

SKYEN/A

VSBCN/A

Rule of 40

SKYE0.0

VSBC0.0

EV/GP/RG

SKYEN/A

VSBCN/A

Ticker research

View SKYE research View VSBC research

Metric	SKYE Skye Bioscience Inc	VSBC Vitaspring Biomedical Co. Ltd
Market & Valuation
Market Cap	$59M	$7M
Enterprise Value	$51M	$9M
Price	$1.69	$0.00
P/E Ratio	N/A	N/A
P/S Ratio	26.57x	0.99x
EV/Sales	0.00x	0.99x
EV/EBITDA	0.00x	4.29x
P/B Ratio	0.83x	3.92x
P/FCF Ratio	N/A	765.53x
EV/FCF	-1.31x	1,044.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	307.4%	0.0%
Profitability
Gross Margin (TTM)	39.3%	39.3%
Operating Margin (TTM)	0.0%	23.4%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	18.2%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-50M	$-456K
FCF (TTM)	$-39M	$9K
EPS (TTM)	-$10.18	-$0.00
ROE (TTM)	-21727.0%	70.0%
ROA (TTM)	-20179.0%	-211240.0%
ROIC (TTM)	-21675.0%	70.0%
Financial Health
Cash	$9M	$13K
Debt	$143K	$2M
Net Cash/Debt	$8M	$-2M
Current Ratio (TTM)	0.95x	0.00x
Quick Ratio (TTM)	0.91x	0.00x
Debt/Equity (TTM)	0.03x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.13	-1.47
52W Performance	-87.7%	-100.0%
YTD Performance	-75.9%	-100.0%
% from 52W High	-88.0%	-100.0%
% from 52W Low	12.7%	N/A
Efficiency & Yields
Asset Turnover (TTM)	1.93x	2.66x
FCF Yield (TTM)	-65.4%	0.1%
Earnings Yield (TTM)	-85.0%	-6.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View SKYE research	View VSBC research